fibrosis-4/5 index; fibrosis-4/5 score; FIB-4/5 index; FIB-4/5 score
Jump to navigation
Jump to search
Indications
- estimation of hepatic fibrosis in liver disease
Procedure
- fibrosis-4 score
- derived from age, serum AST, serum ALT & platelet count
- can be obtained using online calculators[2][3][4]
- derived from age, serum AST, serum ALT & platelet count
- fibrosis-5 score[7]
- derived form waist circumference, body mass index (kg/m2), diabetes mellitus, serum AST, & platelet count
Interpretation
- patients with a score of < 1.3 are unlikely to have fibrosis & should be periodically reassessed[5]
- further evaluation by transient elastography for patients with a score of > 1.3[5]
- patients with FIB-4 scores of 1.3-2.67 should have transient elastography with FibroScan[6]
- patients with low liver stiffness < 8 kPa can be followed in primary care
- patients with intermediate liver stiffness > 8 kPa or high > 12 kPa should be referred to a hepatologist
- patients with FIB-4 scores > 2.67 should be referred to a hepatologist[6]
More general terms
Additional terms
References
- ↑ Sterling RK, Lissen E, Clumeck N et al Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43:1317-1325. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16729309
- ↑ 2.0 2.1 Fibrosis-4 (FIB-4) Index for Liver Fibrosis Noninvasive estimate of liver scarring in HCV & HBV patients, to assess need for biopsy. https://www.mdcalc.com/calc/2200/fibrosis-4-fib-4-index-liver-fibrosis
- ↑ 3.0 3.1 Fibrosis-4 (FIB-4) Calculator University of Washington https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4
- ↑ 4.0 4.1 FIB-4 Calculator https://www.omnicalculator.com/health/fib-4
- ↑ 5.0 5.1 5.2 Rinella ME et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023 May; 77:1797. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36727674 https://journals.lww.com/hep/Fulltext/2023/05000/AASLD_Practice_Guidance_on_the_clinical_assessment.31.aspx
- ↑ 6.0 6.1 6.2 Kanwal F, Shubrook JH, Adams LA et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021 Nov; 161:1657. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34602251 https://www.gastrojournal.org/article/S0016-5085(21)03384-9/fulltext
- ↑ 7.0 7.1 van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction. Gastroenterology. 2024 Mar 19:S0016-5085(24)00300-7 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38513745 https://www.gastrojournal.org/article/S0016-5085(24)00300-7/fulltext?